The use of siRNA to CHK1 or CHK2does not abrogate the damage-induced stabilization of p53 [43], and theknockout of CHK2 in cancer cell lines does not compromise Ser20 sitephosphorylation [44]. The gene discussed is TP53; the disease is cancer.